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ABSTRACT The interaction between human
p53 and MDM2 is a key event in controlling cell
growth. Many studies have suggested that a p53
mimic would be sufficient to inhibit MDM2 to re-
duce cell growth in cancerous tissue. In order to
design a potent p53 mimic, molecular dynamics
(MD) simulations were used to examine the binding
interface and the effect of mutating key residues in
the human p53–MDM2 complex. The Generalized
Born surface area (GBSA) method was used to esti-
mate free energies of binding, and a computational
alanine-scanning approach was used to calculate
the relative effects in the free energy of binding for
key mutations. Our calculations determine the free
energy of binding for a model p53–MDM2 complex to
be 7.4 kcal/mol, which is in very good agreement
with the experimentally determined values (6.6–
8.8 kcal/mol). The alanine-scanning results are in
good agreement with experimental data and calcula-
tions by other groups. We have used the information
from our studies of human p53–MDM2 to design a
-peptide mimic of p53. MD simulations of the mimic
bound to MDM2 estimate a free energy of binding of
8.8 kcal/mol. We have also applied alanine scan-
ning to the mimic–MDM2 complex and reveal which
mutations are most likely to alter the binding affin-
ity, possibly giving rise to escape mutants. The
mimic was compared to nutlins, a new class of
inhibitors that block the formation of the p53–
MDM2 complex. There are interesting similarities
between the nutlins and our mimic, and the differ-
ences point to ways that both inhibitors may be
improved. Finally, an additional hydrophobic pocket
is noted in the interior of MDM2. It may be possible
to design new inhibitors to take advantage of that
pocket. Proteins 2005;58:222–234.
© 2004 Wiley-Liss, Inc.
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INTRODUCTION
The 53-kDa phosphoprotein p53 plays a key role in
maintaining the genomic integrity of cells. In response to
DNA damage and other types of stress stimuli, p53 causes
cell-cycle arrest1 or activates apoptosis.2,3 In normal cells,
p53 is held in check until needed by MDM2 (the murine
double-minute clone 2, more appropriately termed human
double-minute clone 2, or HDM2, for our system).4 Detri-
mental mutations of p53 are common mechanisms for the
loss of p53 wild-type activity in cancer cells.5 But another
important mechanism is overexpression of MDM2, which
leads to constitutive inhibition of p53; this is commonly
seen in cancerous cells containing wild-type (WT) p53.6–9
Because of its importance in cancer development, the
p53–MDM2 complex is a target for anticancer drug design.
It has been shown that a p53 homologue is sufficient to
induce p53-dependent cell death in cells overexpressing
MDM2.10 It has been shown that a peptide as short as 6
residues could bind to MDM2 in the same manner,11 and
medicinal chemistry modifications to that 6-residue pep-
tide dramatically increased its inhibitory activity.12 Small
p53 mimics would be expected to disrupt the p53–MDM2
complex, consequently liberating p53 to initiate cell-cycle
arrest or apoptosis. This anti-MDM2 approach has been
shown to reestablish p53 activities in malignant tissues
with amplified MDM2 genes. The most recent advance has
been the discovery of nutlins: small, multicyclic, hydropho-
bic antagonists that associate to MDM2 within the binding
cleft that recognizes p53.13 These inhibitors are able to
induce apoptosis via the p53 pathway in cancer cells.
The first calculation of the p53–MDM2 system was a
400-ps molecular dynamics (MD) simulation by Massova
and Kollman.14 In that study, a computational alanine-
scanning method was introduced to evaluate the indi-
vidual contributions to the binding free energy for each
residue in the key helix of p53. In order to design an
effective p53 mimic as an inhibitor of human MDM2, it is
important to understand the p53–MDM2 interaction at
the atomic level. More importantly, the design process will
benefit from understanding the influence of MDM2’s indi-
vidual residues on the free energy of binding. To achieve
these goals, we have conducted MD simulations and
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computational alanine scanning for the p53–MDM2 com-
plex, focusing on MDM2.
We have used the information from our simulations to
design a mimic of p53 based on -proline (an isomer of
-proline). These designs build off our previous ab initio
calculations of the conformational properties of -proline
helices.15,16 -Peptides are amino acids with the carboxylic
acid functionality at C rather than C. The difference in
the chiral center allows -peptides to resist hydrolysis by
proteases in the body, giving them different absorption,
distribution, metabolism, and excretion (ADME) proper-
ties than -peptides.17–19 Biomimetic polymers like these
hold promise for new biomaterials and therapeutics,20–22
and this study shows how they may be used in structure-
based drug discovery to target protein–protein recognition
events in cancer cells.
COMPUTATIONAL METHODS
The MD simulations and computational alanine-scan-
ning calculations were performed with the AMBER6.023
suite of programs using the AMBER94 force field24 (the
-proline inhibitor required additional ester parameters
from AMBER99; see supplemental information). The crys-
tal structure of the human p53–MDM2 complex [Protein
Data Bank code: 1YCR]25 was used. In the crystallization
study, residues 17–125 of human MDM2 were used, but
only residues 25–109 were resolved in the crystal struc-
ture. In our simulations, the amino terminus (E25) and the
carbonyl terminus (V109) of MDM2 were capped with an
acetyl group (ACE) and an N-methyl group (NME), respec-
tively. Similarly, the N-terminus of the p53 helix (E17)
was capped with ACE group because of the absence of
electron density for residues 15 and 16 of p53 (the 15–29
stretch of p53 was used in the crystallization). Our simula-
tions used a 13-residue stretch of p53 (Ac-ETFSDL-
WKLLPEN-COO-) in complex with MDM2 to be consistent
with the crystal structure determination. Hydrogens were
added to the protein using AMBER.
Molecular Dynamics
We performed the MD simulations on 5 different sys-
tems: the p53–MDM2 complex, p53 alone in solution,
MDM2 alone, MDM2 complexed with our -proline mimic,
and the mimic alone. All systems were solvated by cubic
boxes of TIP3P water,26 which extended at least 12 Å away
from any given protein atom. The MDM2 system had a net
charge of 5, so 5 chloride ions were added to neutralize
the system. In a similar way, 2 chloride ions were added to
neutralize the p53–MDM2 system, and 3 sodium ions were
added to the p53 system. Our mimic is net neutral and
required no counterions. The mimic–MDM2 complex re-
quired 5 chloride ions. We used the Poisson–Boltzmann
electrostatics module of the Molecular Operating Environ-
ment package (MOE)27 to visualize the field at 8 Å and 10
Å from the protein surface. We placed the ions at the most
charged locations on those surfaces.
The SANDER_CLASSIC module of the AMBER6.0 pack-
age was used for the MD simulations. The particle mesh
Ewald method28 was used to treat the long-range electro-
statics. Periodic boundary conditions and a 10-Å cutoff for
nonbonded van der Waals (vdw) interactions were applied.
All bonds involving hydrogen atoms were constrained
using the SHAKE algorithm. Constant temperature and
pressure (300 K/1 atm) were maintained. A 2-fs timestep
was used to integrate the equations of motion.
The following equilibration protocol was applied to all
systems: First, the water molecules were energy-mini-
mized for 500 steps using the Steepest Descent algorithm,
while holding the solute frozen, followed by minimization
of the protein systems (including the counterions) for 500
steps, while holding the water frozen. Subsequently, the
whole system was subjected to 500 steps of minimization
to remove close contacts and to relax the system. Finally,
the whole system was subjected to a gradual temperature
increase from 10 K to 300 K in 6 intervals over 30 ps. The
whole system was then equilibrated for 100 ps. After this,
2 ns of averaging was conducted. Coordinates were saved
every 1 ps for a total of 2000 snapshots. The resulting
trajectories were analyzed using the PTRAJ and CARNAL
modules of AMBER6.0.
Free Energy Calculations
The GBSA (molecular mechanics/Generalized Born sur-
face area) method29,30 was used to calculate the free
energy of binding (Gbind). One can estimate the binding
free energies to estimate the binding of p53 or the mimic to
MDM2 using the following equations:
Gbind  Gwater(complex)
 [Gwater(MDM2)  Gwater(ligand)],
where Gwater is the average free energy of the system in
solution calculated by the following:
Gwater  Egas  Gsolvation  TS
Egas  Ebond  Eangle  Etorsion  Evdw  Eelectrostatic
Gsolvation  GGB  Gnonpolar,
where Egas is the sum of the bond, angle, torsion, vdw, and
electrostatic terms from the conformations saved from the
MD simulation. The “gas” notation indicates that the total
energy term does not include the interaction between the
solutes and the surrounding explicit water molecules or
ions from the MD simulation. The absolute energy, Egas,
was calculated using the ANAL module in the AMBER6.0
package. All energy components and solvation contribu-
tions were calculated using trajectories from 3 systems
(the ligand–MDM2 complex, the unbound MDM2, and the
unbound ligand, where the ligand can be the p53 helix or
our -proline mimic).
The free energy of solvation (Gsolvation) includes polar
(GGB) and nonpolar contributions (Gnonpolar). The polar
electrostatic contribution was estimated using General-
ized Born theory (employing the program GB31 in the
AMBER package). The nonpolar contribution to the solva-
tion free energy was estimated according to the equation,
Gnonpolar  	*SASA  , where SASA is the solvent-
accessible surface area calculated by the program MSMS
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and the default values of 	 and  were used (	  0.00542
kcal/Å2 and   0.92 kcal/mol).32
The average entropy, S, for each system was calculated
from 11 snapshots taken every 200 ps from the 2-ns
trajectory. The entropy was estimated using normal mode
analysis (employing the NMODE module33,34 of AMBER).
To prepare structures for the normal mode calculations,
the water and counterions were removed from each snap-
shot, and the protein structure was energy-minimized.
After minimization, the conformation was compared to the
original snapshot; all resulting conformations had a root-
mean-square deviation (RMSD) less than 2 Å to the
original snapshot, indicating that those structures were
representative of the structures sampled in the MD simu-
lations.
Computational Alanine Scanning
Key residues of MDM2 were chosen from the binding
interface: L54, L57, I61, M62, Y67, Q72, F91, V93, H96,
I99, and Y100. Each of these residues is within 4 Å of p53
and the -proline mimic. We calculated the relative change
in free energy of binding (Gbind) for the alanine mutants
of these residues in MDM2 using GBSA. The alanine
mutants were created by truncating the key residue in the
snapshots from the MD simulations of the WT MDM2–
ligand complexes. For this calculation, we followed the
original protocol outlined by Massova and Kollman,14
which assumes that the entropy of the mutant is not signifi-
cantly different than the WT and the components for Gbind
come only from the changes in Egas and Gsolvation. Gbind
was calculated by comparing the Gbind of the alanine
mutant to the Gbind of the WT.
RESULTS AND DISCUSSION
Molecular Dynamics of p53–MDM2 Systems
In order to examine the binding interface and estimate
the free energy of binding for the p53–MDM2 complex, we
performed 2-ns MD simulations on 3 different systems: the
p53–MDM2 complex, the unbound MDM2, and the un-
bound p53. The potential energy of the protein systems
over the course of the simulations is given in the supple-
mental information. The energies of the 3 systems indicate
that all were stable over the 2-ns simulations.
The stability of the simulations is further demonstrated
in Figure 1, with the RMSD of the C atoms compared over
the course of the simulation. The trajectory of the unbound
MDM2 is quite stable over the timescale of the simulation,
with an average RMSD less than 1.0 Å [gray line in Figure
1(B)]. The RMSD of the p53–MDM2 complex was under
1.0 Å during the first nanosecond, but a rise in the RMSD
is observed between 1.0 and 1.7 ns. As seen in Figure 1(A),
the increase comes from the p53 helix in the p53–MDM2
complex. The N-terminus of the p53 helix unwound slightly
and sampled more conformational space in the section half
of the simulation [Fig. 2(A)]. This terminus is partially
unresolved in the crystal structure, so higher flexibility is
expected.
For the unbound p53 system [the black line in Fig. 1(B)],
the RMSD continues to increase over the simulation,
caused primarily by more motion in the side chains and
the C-terminus. Massova and Kollman also observed a
great deal of flexibility for the unbound p53 helix.14 It
appears that the structure of the short p53 sequence is
stabilized by the hydrophobic binding cleft of MDM2, and
its helical structure is not as stable in solution [Fig. 2(B)].
Short peptides are often highly flexible in solution, and the
p53 helix appears to follow this trend. The side chains of
F19 and W23 swing freely over the 2-ns simulation [Fig.
2(B)]. The average RMSDs for the F19 and W23 side
chains from the unbound p53 simulation are 2.5 Å and 3.5
Å, respectively. However, the F19 and W23 side-chains of
p53 complexed to MDM2 sampled much less conforma-
tional space (average RMSD of 1.5 Å and 1.2 Å, respec-
tively). This suggests that the hydrophobic interaction
between MDM2 and p53 helps to stabilize and maintain
the p53 helix. The small degree of conformational sam-
pling in the complex also suggests the importance of
properly oriented aromatic groups for a successful steric
complement to the MDM2 binding pocket.
Fig. 1. (A) The RMSDs for the C atoms are provided for the complex
of human p53–MDM2 (thick black line), MDM2 in the complex (thick gray
line), and p53 in the complex (thin gray line). All 3 plots were calculated
from an overlay of all C atoms in the complex. (B) The RMSDs for the C
atoms in the simulations of unbound p53 (thick black line) and unbound
MDM2 (thin gray line).
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Free Energy Calculations
The apparent Kd for the helix of p53 (residues 15–29
used in the crystal structure) is 600 nM at 35°C (8.8
kcal/mol).25 The IC50 for the binding of a sequence from
human p53 (Ac-QETFSDLWKLLP-NH2) to MDM2 is 2–14

M as reported by Böttger et al.11 This IC50 range
corresponds to a free energy of binding between 6.6 and
7.8 kcal/mol.14 The sequence that we used from the
crystallographic study is slightly different, but we assume
that the binding affinity should be similar. The contribu-
tions to the free energy of binding for the p53–MDM2
complex are listed in Table I and were obtained using the
GBSA method. The electrostatic energy is balanced by the
free energy of solvation, so it appears that the vdw energy
drives the association. Our calculated Gbind for p53–
MDM2 is 7.4 kcal/mol. This is in excellent agreement
with related experimental values. Despite some conforma-
tional sampling of the p53 helix toward the end of 2 ns of
MD, the Gbind values are consistent across the simula-
tion. It appears that last few residues in the N-terminus of
the p53 helix do not contribute as significantly to binding
as residues that interact with the cleft.
Entropic Component
When using the GBSA method to calculate the binding
free energy, careful protocol should be used when applying
the NMODE method to estimate the entropic contribution
(S). We adopted a different way to estimate entropy than
was originally proposed. In the original presentation of the
method,14 only the crystal structure was used to estimate
the entropy. Since the energy components and the related
free energy components are the average of all 2000 snap-
shots from the 2-ns simulations, it is more appropriate if
we use several snapshots from the MD to calculate the
entropy. Using all 2000 snapshots was prohibitively time-
consuming, so we used 11 snapshots (the equilibration
structure plus structures from every 200 ps) to calculate
an average entropy, S.
The original paper also presented a second approxima-
tion with respect to entropy. The conformations of the
proteins in the crystal structure were used to estimate the
entropy of the complex and also to estimate the entropies
for MDM2 alone and for the p53 helix alone. We evaluated
2 methods to determine the average entropy of the un-
bound MDM2 and p53. Our first method was similar to the
Fig. 2. Snapshots from the 2-ns MD simulations are color coded from early (dark blue and green) to middle
(yellow) to late (red and purple) in the simulation. The backbone of MDM2 is shown in gray for all snapshots,
and all figures are drawn to the same scale. (A) The conformational sampling of the backbone of p53–MDM2
with F19, W23, and L26 highlighted. (B) Structures of unbound p53 show that the hydrophobic groups have
wide conformational sampling; p53 seems less stable in the absence of MDM2. (C) Conformational sampling of
the mimic–MDM2 complex. (D) In the unbound mimic, the aromatic rings also show wide conformational
sampling (atoms shown in ball-and-stick configuration), but the backbone is very stable (atoms shown in stick
model).
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original methodology, because we estimated the entropy of
the complex and components using only snapshots from
the simulation of the p53–MDM2 complex. Using the first
method, we were able to reach agreement with experiment
and calculate Gbind to be 7.4 kcal/mol. The second
method calculated each system’s average entropy using
snapshots from separate trajectories of the complex (p53–
MDM2), MDM2 alone in solution, and p53 alone. Using the
second method, Gbind was calculated to be 14.1 kcal/
mol. This is much higher than the experimental IC50’s
imply and would indicate incredibly tight binding. The
second method appears to overestimate the entropy, but
the cause is unclear. Independent sampling for the un-
bound components should be a more accurate procedure
for estimating entropic changes upon binding.
Our use of independent trajectories for calculating the
entropic change upon binding was not successful, but our
use of longer sampling and an average entropy term
appears to be an improvement over the original implemen-
tation by Massova and Kollman.14 They calculated a
smaller free energy of binding for the human p53–MDM2
complex, between 4.5 and 5.7 kcal/mol (still good
agreement with the experimental values given the approxi-
mate nature of the methodology). Our higher Gbind may
also be due to our use of a slightly different sequence for
the p53 helix. We have also chosen to use the GB method to
estimate electrostatics rather than the Poisson–Boltz-
mann electrostatics used by Massova and Kollman.
Alanine Scanning Within the Binding Cleft of
MDM2
The alanine-scanning methodology is based on the as-
sumption that replacing the original residue with an
alanine will only introduce local changes and not cause a
large conformational change to alter the binding mode.
Also, the small local changes are assumed to have little
effect on entropy, so the entropic term (TS) for the
wild-type and the mutants should cancel when calculating
Gbind. Therefore, Gbind is defined as Gbind(WT) 
Gbind(Ala mutant), but is only calculated using the Egas
and Gsolvation components.
The crystal structure reveals that the interaction be-
tween MDM2 and p53 relies primarily on vdw contacts
and steric complementarity.25 Residues F19, W23, and
L26 of p53 make extensive contacts with MDM2’s hydro-
phobic cleft. For residues of p53, experimental and compu-
tational studies have shown that mutants of the hydropho-
bic residues reduce or eliminate binding, but mutations of
polar or charged residues have little effect upon the
binding activity.14,35–37 We verified our computational
approach by calculating the Gbind for p53 mutants
T18A, F19A, S20A, and W23A, and comparing the results
to previous calculations and experimental values. Our
calculated Gbind are 4.7 kcal/mol for W23A and 3.0
kcal/mol for F19A. Values for T18A and S20A are 0.9
kcal/mol and 0.7 kcal/mol. These values parallel Massova
and Kollman’s calculations (Gbind of 5.54, 2.71,
0.04, and 0.72 kcal/mol, respectively).14 The results for
W23A, F19A, and T18A are within 1 kcal/mol of Massova
and Kollman’s results, which is exceptional agreement.
Even the S20A values, though different in sign, are well
within the typical error bars for this methodology and
point to a minimal effect of mutating S20 (less than 1
kcal/mol). The calculated Gbind also agree with the
experimental trend that mutants of W23 and F19 abolish
p53 binding, while mutations of T18 and S20 are tolerated.
The effects of mutating the residues within MDM2 are
not as well understood. Residues of MDM2 with significant
influence on the binding (so-called binding hotspots) are
important to medicinal chemists for drug-design purposes.
In order to determine which residues are most influential,
we applied computational alanine scanning to 11 residues
TABLE I. Energy Components and Free Energy of Binding for the Human p53-MDM2 Complexa
Contributions
(kcal/mol)
p53–MDM2 Complex Receptor (MDM2) Ligand (p53)
average std dev average std dev average std dev
Eelectrostatic 2927.0 88.8 2388.8 42.6 177.7 20.4 360.4
Evdw 396.2 20.0 322.7 14.7 9.8 4.7 63.8
Einternal 1681.5 28.3 1456.4 26.5 214.5 9.9 10.6
Egas 1641.7 100.4 1255.1 47.7 26.9 22.7 413.5
Gnonpolar 45.7 1.3 42.5 0.6 13.4 0.3 10.2
GGB 1232.2 82.6 1169.3 39.1 432.2 17.7 369.2
Gsolvation 1186.5 82.1 1126.8 38.8 418.7 17.7 359.0
Egas  Gsolvation 2828.2 33.6 2381.8 26.4 391.8 10.4 54.5
TSb 1108.5 5.3 970.6 2.9 185.0 2.9 47.1
Gbind
b 7.4
TSc 1108.5 5.3 971.4 4.7 177.6 2.0 40.5
Gbind
c 14.1
aAny small discrepancies are due to rounding to the first decimal place.
bEntropy was estimated based on structures from the trajectory of the complex only. Gbind from experiments is between
6.6 and 8.8 kcal/mol. Our calculated Gbind of 7.4 kcal/mol is in very good agreement with the experiments, indicating
the reliability of the MM-GBSA method coupled with this approach to estimating the entropy.
cEntropy was estimated based on separate trajectories of the complex, MDM2, and p53.
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with side chains in contact with p53 and our mimic: L54,
L57, I61, M62, Y67, Q72, F91, V93, H96, I99, and Y100.
Many of these residues are conserved across different
species,14,25 and they may be essential for binding p53.
The crystal structure of the human p53–MDM2 complex is
available,25 but the structure does not quantify the influ-
ence of each residue in terms of ligand binding.
Table II shows the relative free energies of binding for
the alanine mutants of the 11 residues of MDM2. The
relative free energies of binding are defined as
Gbind(WT)  Gbind(Ala), so negative values for Gbind
imply that the mutation to alanine is unfavorable. The
results show that there is a significant loss of binding
affinity when many of the residues are mutated to alanine.
The most detrimental mutation is Y100A, which loses over
6 kcal/mol of binding free energy. Alanine mutants of L54,
Y67, Q72, or H96 cost 3.0–3.5 kcal/mol of binding free
energy. Similarly, the mutation of residues I61, M62, or
V93 to alanine is also unfavorable, since the change in
Gbind is 2.5 to 3.0 kcal/mol.
As seen in Table II, the replacement of Y100 with
alanine was accompanied by a loss of 3.5 kcal/mol in vdw
interactions and 11.1 kcal/mol in electrostatic energy.
During the MD simulations, there are hydrophobic interac-
tions between Y100 and P27 of p53. The stronger electro-
static component above is the result of a hydrogen bond
between the phenolic OH of Y100 and the C-terminal acid
of our p53 helix (the strength of that interaction will be
slightly different between the actual complex of p53 and
MDM2, because the peptide chain will not terminate at
that residue). The mutation of Q72 to alanine results in a
loss of 4.4 kcal/mol in electrostatic energy and 2.7 kcal/mol
of vdw interaction. During the MD simulation, the side-
chain of Q72 forms a hydrogen bond with the backbone
nitrogen of F19 in p53.
The major loss when mutating residues L54, I61, M62,
Y67, V93, or H96 to alanine is the loss in vdw interaction.
Residue L54 of MDM2 packs directly against W23 and L26
of the p53 helix. Though the side chain is critical to the
hydrophobic surfaces of the pocket, it is the backbone
oxygen of L54 that participates in a hydrogen bond with
the indolyl nitrogen of W23 in p53. This hydrogen bond is
not lost upon mutating the side chain, so little change is
seen in the electrostatic energies. Residues I61 and V93 of
MDM2 interact with both F19 and W23 of p53, two critical
residues for favorable hydrophobic interaction in the com-
plex. The structures from the MD simulations show that
there are favorable vdw interactions between the phenyl
ring of Y67 in MDM2 and the phenyl ring of F19 of p53.
M62 also has significant vdw interactions with the aro-
matic ring of F19. MDM2’s H96 interacts with P27 and 2
leucine residues in the p53 stretch. Many contacts between
TABLE II. Relative Free Energies of Binding (kcal/mol) for Alanine Mutants of Human MDM2
Complexed With a 13-residue Helix From the Sequence of Human p53a
Contribution L54A L57A I61A M62A
Eelectrostatic 1.1 0.2 0.2 0.7
Evdw 3.6 0.7 2.1 2.5
Egas 4.7 0.8 2.3 3.2
Gnonpol 0.1 0.1 0.2 0.3
GGB 1.2 0.1 0.6 0.7
Gsolvation 1.1 0.1 0.5 0.4
Gbind
b 3.5c 0.7 2.7 2.8
Interacts with residues of p53 W23, L26, E28 W23 F19, W23 F19, S20
Contribution Y67A Q72A F91A V93A
Eelectrostatic 0.9 4.4 0.0 0.1
Evdw 2.2 2.7 0.8 2.9
Egas 3.1 7.1 0.8 3.0
Gnonpol 0.1 0.3 0.2 0.0
GGB 0.1 4.1 0.4 0.4
Gsolvation 0.1 3.8 0.1 0.4
Gbind 3.2 3.3 0.9 2.5
Interacts with residues of p53 F19 E17, T18, F19, L22 W23 F19, L22, W23
Contribution H96A I99A Y100A
Eelectrostatic 1.3 0.2 11.1
Evdw 4.8 1.5 3.5
Egas 3.5 1.7 14.6
Gnonpol 0.3 0.1 0.3
GGB 0.4 0.3 8.4
Gsolvation 0.1 0.4 8.2
Gbind 3.4 1.2 6.4
Interacts with residues of p53 L25, L26, P27 W23, L26 P27, N29
aAny small discrepancies in this table are due to rounding to the first decimal place.
bGbind  Gbind(WT)  Gbind(mutant). Negative numbers indicate that the mutation to alanine is unfavorable.
cNumbers in bold indicate residues with the most critical contributions (Gbind of 2.5 kcal/mol or less).
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H96 and p53 indicate that H96 is another binding hotspot,
and this is confirmed by a Gbind of 3.4 kcal/mol.
Residues L57, F91, and I99 do not appear to be as
influential for binding as the other hydrophobic residues in
the cleft. The smaller contributions from these 3 residues
are not obvious from examining the crystal structure of the
complex. This underscores the usefulness of the alanine-
scanning calculations.
Experimental mutagenesis studies have shown G58 to
play an important role in binding. The G58 mutants of
MDM2 do not interact with p53 in vitro and fail to inhibit
p53-dependent transcription in vivo.38 Inherent limita-
tions in the alanine-scanning methodology prevent us
from quantifying the influence of mutating a glycine, but
the MD simulations show tight packing between G58 and
the aromatic rings of p53 and our mimic when bound.
There was little conformational sampling over the 2 ns for
G58; the average RMSD for residue G58 over 2000 snap-
shots was only 0.8 Å. Mutating G58 to any other residue
would likely reduce binding by disrupting the interaction
between G58 in MDM2 and the aromatic rings of p53.
These results are in good agreement with experimental
results and previous computational studies. Levine and
coworkers showed that deletion of residues 43–58, 59–89,
or 90–122 from MDM2 eliminated its ability to bind p53.39
Leng et al. showed that the deletion of residues 1–58 or
residues 60–65 significantly weakened binding of p53.40
These regions encompass the major residues: L54, I61,
M62, Y67, Q72, V93, H96, and Y100. These experimental
studies support our findings, but that support is limited,
since deletion of large sections of the protein alters the
structure of MDM2 much more than the alanine mutants
presented here. However, our results are in excellent
agreement with recent computational studies of Xenopus
laevis p53–MDM2 (the binding domain of X. laevis MDM2
has 65% sequence identity to HMD2).
Kortemme and Baker have recently developed a very
interesting approach to alanine-scanning calculations.37 In
applying their faster method to p53–MDM2 from X. laevis,
they identified Y67, Q72, V93, and Y100 as hotspots for
binding. Our calculations agree with the X. laevis data and
add L54, I61, M62, and H96 to the list of potential hotspots
for human MDM2. Our addition of these 4 residues may
come from the differences in our approaches to in silico
alanine scanning, or it may be the result of our focus on the
human p53–DM2 system. The difference in sequence be-
tween X. laevis and human MDM2s causes small structural
differences that may affect the binding cleft.
Designing a Mimic of p53 Based on -Proline
Given the stability of the complexes in the aforemen-
tioned MD simulations and the excellent agreement with
experimental free energies of binding, we can assume that
these methods provide a reliable means of designing and
evaluating potential p53 mimics.
Based on the crystal structure, the MD simulations, and
the free energy calculations, we know the importance of
hydrophobic complementarity between p53 and MDM2. The
alanine-scanning calculations and experimental mutagen-
esis studies have shown that F19 and W23 are the most
important residues for the binding of p53. Therefore, our
mimic must provide aromatic rings to interdigitate MDM2’s
binding cleft, similar to the side chains of F19 and W23.
An ideal mimic of p53 should consist of (1) a small,
helical scaffold that (2) contains side chains similar to
phenylalanine and tryptophan, with (3) the proper spacing
and orientation to complement MDM2. Short -peptides
have been shown to fold into helices, sheets, and turns that
are common secondary structures in proteins.16–22 We
turned to oligomers of -proline, (S)-pyrrolidine-3-carboxy-
lic acid, as potential scaffolds for the p53 mimic. We have
experience calculating the conformational behavior of
monomers, dimers, and hexamers of -proline.15,16 Our ab
initio calculations at the RHF/6-31G* level of theory have
shown that a -proline hexamer can fold into regular
helical structures. Both right- and left-handed helices are
possible for multimers of -proline, making them a good
choice for a short helical scaffold. Unsubstituted -proline
is not rigid in solution, but its conformational freedom is
less than a short -peptide, like the p53-based helix used
in the modeling and experimental studies discussed above.
Figure 3 shows our process for analyzing the -proline
helices to design potential mimics of p53 based on the
geometric criteria outlined below. In the crystal structure
of human p53–MDM2,25 the distance between the C’s of
F19 and W23 is 5.9 Å; the C–C distance in the MD
simulations of the p53–MDM2 complex remains very close
to that value, with an average distance of 6.0 Å. In the MD
simulations, the RMSDs of all atoms in F19 and W23 are
only 1.5 Å and 1.2 Å, respectively. These data indicate that
the mimic will have to closely match the positions and
orientations of F19 and W23. Because the RMSD is a little
larger for F19, the benzyl side chain is the one that could
be varied a little more in the design of a mimic. The mimic
requires side chains that are 5.9  1.0 Å apart. This
distance is based on the crystallographic positions, and the
variance is a conservative choice based on the RMSD of
W23. The relative orientations of the aromatic side chains
are best described by the torsional relationship between
C–C in F19 and C–C in W23. This torsional angle
[C(F19)-C(F19)-C(W23)-C(W23)] is 16.8° in the crys-
tal, and the average value in the MD simulation is 34.7°.
Based on these data, the mimic needs side chains that
have a torsional relationship of 17  18°.
The hexamers from our RHF/6-31G* calculations15
proved to be too long to fit the cleft for MDM2, but
tetramers were approximately the correct length. The 4
lowest energy conformers of the -proline helices were
analyzed. The conformers of the enantiomer of -proline,
(R)-pyrrolidine-3-carboxylic acid, were also investigated,
but successful designs were not possible (data not shown).
All pairs of carbons on the -proline rings were evaluated
as potential substitution points. When pairs of carbons
were found that fit the distance criterion (mimicking the
two key C in p53), their COH bonds were compared to the
torsional angle requirement.
After identifying appropriate positions for the aromatic
groups, a benzyl side chain (to mimic F19) and an indolyl
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moiety (to mimic W23) were introduced into the -proline
scaffold. The disubstituted tetramers were fit into the MDM2
pocket through superimposing the -proline to the p53
sequence according to the COC bonds of the F19 and W23
side chains. The tetramers and binding-site residues were
then energy-minimized to optimize the fit between the mimic
and MDM2. Our best p53 mimic based on the -proline
scaffold is shown in Figure 4; it was chosen based on (1) the
relative interaction energy after minimization and (2) the
complementarity between the surfaces of the mimic and the
MDM2 cleft (data not shown).
The favorable interaction energy is due to the intrinsic
hydrophobicity of both surfaces and the ability of the
-proline scaffold to adopt regular helical structure, pre-
senting the aromatic side chains in the proper orientation.
Figure 4 shows the mimic–MDM2 complex superimposed
on the p53–MDM2 complex. The mimic appears to be very
similar to p53 in terms of the steric complementarities to
the hydrophobic cleft and the hydrogen bond between the
indolyl nitrogen and the backbone oxygen of L54 in
MDM2. No additional group was necessary to mimic L26,
another critical hydrophobic residue in p53, because the
N-terminal -proline ring has favorable interactions with
Fig. 3. The evaluation of key residues within p53 to design similar components into the -proline scaffold.
The -proline helices shown with green carbons are from a previous study15; these are the lowest energy
conformers. Both N3C and C4N directions were evaluated for all conformations of the -proline scaffold.
Within the binding cleft, -peptides do not necessarily have to lie in the same direction as -peptides, especially
when the p53 helix is capable of internal hydrogen bonding and the mimic is not. The final design of our optimal
mimic is based on the middle structure, and it is shown in Figure 4.
Fig. 4. The similarity between the mimic (ball-and-stick configuration
with green atoms) and p53 is shown in an overlay of the complexes of
p53–MDM225 and the mimic–MDM2. The p53 helix has a C4N orienta-
tion in this view, but the optimal fit with the mimic was an N3C orientation
(the side chains are noted in yellow and the -proline rings are numbered
in green). For clarity, the hydrogens and the protein are not shown.
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the binding cleft in the appropriate region. The -proline
scaffold has an inherently different helical structure,
which results in the tetramer having additional interac-
tions with the aromatic ring of Y67 (beyond of the surface
complemented by the p53 helix). This does not cause a
significant conformational change in the interacting resi-
due of MDM2. In fact, this new hydrophobic interaction
contributes additional stability to the complex.
Binding Affinity of the Mimic
MD simulations were also performed for the mimic–
MDM2 complex and the unbound mimic. The potential
energies over both simulations indicated that the complex
and the unbound system were stable (data in supplementary
information). The conformational sampling is shown in Fig-
ure 5, with plots of RMSD versus time. The initial 600 ps
show a period of fluctuation as the mimic–MDM2 complex
optimizes its contacts. Over the course of the 2-ns simulation
of the complex, the substituted tetramer accurately mimics
the positions of p53’s F19 and W23; the mimic showed only a
small degree of conformational sampling [Fig. 2(C)], with an
average RMSD of 0.7 Å for the benzyl side chain, 1.0 Å for the
indolyl moiety, and 1.4 Å for all atoms. However, the un-
bound tetramer demonstrated a different behavior, with a
rise in RMSD halfway through the simulation [gray line in
Fig. 5(B)]. The relative stability at the beginning and end of
the simulation might suggest 2 major conformations for the
unbound mimic, caused by a flip of the aromatic rings and a
change in the ring pucker of the third -proline ring [Fig.
2(D)]. The calculated RMSD for the same side chains in the
simulation of the lone mimic are 5.2 Å and 5.7 Å, respec-
tively. The difference between the complex and unbound
state indicates that the hydrophobic interaction with the cleft
of MDM2 helps to maintain the proper orientations of the
aromatic side chains in the complex (this was also the case in
the simulations with the -helix of p53). It is interesting that
the -proline backbone shows little conformational move-
ment in the unbound simulation (RMSD is only 1.2 Å).
The same GBSA method was applied to the mimic–MDM2
complex, the unbound mimic, and the unbound MDM2
calculated previously. As shown in Table III, the estimated
free energy of binding for the mimic was 8.8 kcal/mol. This
indicates that our disubstituted -proline–based tetramer
could be a potent inhibitor for MDM2, with comparable
activity to p53. The mimic is significantly smaller than p53
but reproduces more than half of the vdw interaction energy.
The solvation term is much less of a penalty, which is
expected given the hydrophobic nature of the tetramer.
Together, these factors produce a free energy of binding that
is within error of the value p53 for this method.
Computational alanine scanning was also performed
for the same 11 residues of MDM2 within the binding
site. Table IV shows that the most significant loss of
binding affinity occurs upon mutating Y67 and I61 to
alanine. To a lesser extent, I99, L54, M62, and V93 also
appear to be potential hotspots for binding. Mutating all
of the noted residues to alanine costs a significant
amount of vdw interaction energy. Many of the interac-
tions between MDM2 and the mimic are similar to those
seen in binding p53. For instance, residue I61 has
favorable hydrophobic interactions with both aromatic
side chains of the mimic. This same tight interaction
with F19 and W23 in p53 made I61 a key residue for
binding the natural ligand, too.
The differences between the mimic and the p53 helix are
more interesting, as they may identify residues that are
likely to give rise to escape mutants that evade the mimic
(Table V). As noted above, mutating Y67 to alanine
significantly reduces binding of the mimic. Structures
from the MD simulation indicate that the aromatic ring of
Y67 stacks underneath the last -proline ring of the
tetramer, creating close vdw interactions. Though p53 also
has vdw interactions with Y67, the degree of contact is
much less. Y67 could be a more significant hotspot for our
mimic. The other residue that has more influence in
binding the mimic versus p53 is I99. The first -proline
ring of the mimic and its N-terminal acyl group fits tightly
against the side chain of I99, reaching more deeply into the
Fig. 5. (A) The RMSDs for the C atoms are provided for the
mimic–MDM2 complex (thick black line) and the mimic in the complex
(thin gray line). (B) The RMSDs for the C atoms in the simulations of the
unbound mimic (thin gray line); the RMSDs for the unbound p53 (thick
black line) are provided for reference.
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hydrophobic cleft at that location. This produces greater
vdw interaction energies between I99 and the mimic in the
subpocket for L26 in p53.
Some side chains have stronger interactions with p53
than the mimic. Mutations at these positions would be
less likely to alter the binding of our mimic without also
greatly altering the affinity of p53. For example, Y100
plays an important role when p53 binds to MDM2
through hydrogen bonding to N29 and hydrophobic
interactions with P27. These do not apply to the tet-
ramer–MDM2 interaction. Similarly, the side chain of
Q72 in MDM2 forms a hydrogen bond with the backbone
nitrogen of F19 in p53, but the -proline backbone of the
mimic has no hydrogen-bond donors to engage in the
same strong interaction. Residues H96 and L54 have
many vdw contacts with several C-terminal residues of
the p53 helix. The vdw interaction between those resi-
TABLE III. Energy Components and Free Energy of Binding (kcal/mol)
for the Mimic–MDM2 Complexa
Contributions
(kcal/mol)
Mimic–MDM2 Receptor (MDM2) Ligand (Mimic)
Average std dev average std dev Average std dev
Eelectrostatic 2449.7 71.6 2388.8 42.6 3.5 2.1 57.4
Evdw 351.0 14.8 322.7 14.7 6.0 3.3 34.3
Einternal 1576.8 26.3 1456.4 26.5 107.8 6.5 12.6
Egas 1223.8 74.8 1255.1 47.7 110.3 7.0 79.1
Gnonpolar 43.0 0.8 42.5 0.6 6.7 0.3 6.2
GGB 1154.5 68.1 1169.3 39.1 31.4 2.0 46.1
Gsolvation 1111.5 67.6 1126.8 38.8 24.7 1.9 39.9
Egas  Gsolvation 2335.3 26.6 2381.8 26.4 85.7 6.7 39.2
TSb 1028.1 6.0 976.8 4.6 81.7 0.6 30.4
Gbind
b 8.8
TSc 1028.1 6.0 971.4 4.7 80.4 1.1 23.7
Gbind
c 15.5
aAny small discrepancies in this table are due to rounding to the first decimal place.
bEntropy was estimated based on structures from the trajectory of the complex only. The calculated Gbind of 8.8
kcal/mol indicates that our proposed disubstituted -proline tetramer could be a potent inhibitor for MDM2, with
comparable activity to p53.
cEntropy was estimated based on separate trajectories of the complex, MDM2, and the mimic.
TABLE IV. Relative Free Energy of Binding (kcal/mol)
for Alanine Mutants of MDM2 Complexed
With Our -Proline Mimic of p53a
Contribution L54A L57A I61A M62A
Eelectrostatic 0.2 0.5 0.4 0.5
Evdw 1.9 0.7 2.0 1.9
Egas 1.6 0.1 1.6 1.4
Gnonpol 0.2 0.0 0.1 0.3
GGB 0.4 0.9 1.6 0.4
Gsolvation 0.5 0.9 1.5 0.7
Gbind
b 2.1 1.0 3.1c 2.1
Contribution Y67A Q72A F91A V93A
Eelectrostatic 0.6 0.4 0.6 0.5
Evdw 4.2 2.3 0.8 1.7
Egas 4.8 1.9 0.3 1.1
Gnonpot 0.2 0.3 0.2 0.1
GGB 0.3 0.7 1.0 0.7
Gsolvation 0.6 0.4 0.8 0.8
Gbind 5.3 1.5 1.0 1.9
Contribution H96A I99A Y100A
Eelectrostatic 0.4 0.4 0.6
Evdw 1.6 2.0 0.0
Egas 1.2 1.6 0.6
Gnonpol 0.3 0.1 0.1
GGB 0.2 0.8 0.0
Gsolvation 0.5 0.7 0.1
Gbind 1.6 2.3 0.7
aAny small discrepancies in this table are due to rounding to the first
decimal place.
bGbind  Gbind(WT)  Gbind(mutant). Negative numbers indicate
that the mutation to alanine is unfavorable.
cNumbers in bold indicate residues with the most critical contribu-
tions (Gbind of 2.5 kcal/mol or less).
TABLE V. Comparison of Relative Free Energies of
Binding (kcal/mol) From the Computational Alanine
Scanning for Both Ligands Complexed to Human MDM2a
Side Chain
in MDM2 p53 Mimic Difference
L54A 3.5 2.1 1.4
L57A 0.7 1.0 0.3
I61A 2.7 3.1 0.4
M62A 2.8 2.1 0.7
Y67A 3.2 5.3 2.1
Q72A 3.3 1.5 1.8
F91A 0.9 1.0 0.1
V93A 2.5 1.9 0.6
H96A 3.4 1.6 1.8
I99A 1.2 2.3 1.1
Y100A 6.4 0.7 5.7
aThe greatest differences are highlighted in bold. For Y67A, the
mutation is more detrimental to the binding of the mimic. For Q72A,
H96A, and Y100A, the mutation is more detrimental to the binding of
the p53 helix.
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dues and the mimic is only moderate because the
tetramer is shorter than p53.
Comparing the Mimic to Nutlins
Of course, the mimic introduced here is meant to be a
proof-of-principle exercise to show how one might design
peptide mimics to block protein–protein binding and use
alanine-scanning calculations to predict escape mutants
early in the design process. It was exciting to see similari-
ties to a proven inhibitor of the system. Near the comple-
tion of writing this manuscript, nutlins were introduced as
a new class of small-molecule inhibitors that block the
association of p53–MDM2.13 The similarities between the
mimic and the nutlins were intriguing, because they were
developed in very different ways. The nutlins were discov-
ered through screening diverse libraries of small mol-
ecules, and the mimic was a design rationally based on the
structural features of the p53–MDM2 complexes from the
MD simulations.
Nutlins are also hydrophobic molecules composed of
tethered 5- and 6-membered rings, and the topology is
rather similar (Fig. 6). The second -proline ring of our
mimic plays the same role as the central imidazole ring of
nutlin2. Both the mimic and nutlin2 use a ring off the
central 5-membered ring to occupy the position of L26 in
p53. Aromatic rings occupy the position of W23. A third
aromatic ring off nutlin2’s imidazole ring is a bridging
feature, like the third -proline ring of our mimic. Both
present hydrophobic groups to occupy the position of F19.
The piperazine-based branch of nutlin2 is not mirrored in
the mimic, and the C-terminal -proline ring is not mir-
rored in nutlin2. However, the structures show that the
alcohol group in nutlin2 is within 1 Å of the nitrogen in the
last -proline ring. The differences highlighted in Figure 6
result in the mimic being longer than nutlin2, and nutlin2
slightly wider. Figure 7 shows the mimic–MDM2 complex
and nutlin2–MDM2 complex overlaid.
Improving Inhibitors of p53–MDM2
The nutlins are quite a breakthrough in blocking a key
protein–protein recognition event, but the crystal struc-
ture of the nutlin2–MDM2 complex (1RV1) shows that
nutlin2 has unusual packing characteristics.13 The nutlin
appears to self-associate and also to bind to other faces of
MDM2. It is possible that nutlins may be promiscuous
binders. The differences between the mimic and the nut-
lins point to modifications that could be introduced to
improve the affinity and specificity of both molecules.
Perhaps the mimic’s indolyl ring could be incorporated
into the nutlins or groups could be added to lengthen the
nutlins to occupy the position of the C-terminal -proline
ring of the mimic. Additional groups could be introduced
off the third -proline ring of the mimic to occupy the
region of the piperazine-based branch in nutlin2. Also, the
nutlins use very different aromatic and hydrophobic groups
to complement the pocket, and those groups or other
groups could be introduced to the mimic.
Modifying the hydrophobic groups could have an added
benefit. During our examination of the crystal structures
and the structures from our MD simulations, we discov-
ered a small hydrophobic pocket within MDM2 (Fig. 8).
The pocket is rather close to the binding cleft, and it may
be possible to design inhibitors to take advantage of it. The
pocket is created between L34, L57, L85, F86, I103, and
N106. L57 is one of the residues that complements W23
and the indolyl ring of the mimic. In both cases, the L57A
mutant gives little change in the free energy of binding.
This may indicate that there would be little penalty for
L57 to reorient, filling the interior pocket and deepening
the binding cleft to allow for larger or differently shaped
hydrophobic groups. In the nutlin2–MDM2 structure,13
the hydrophobic pocket is larger and includes L37 and L82
as 2 more residues bounding the space. There may be a
good deal of flexibility in the hydrophobic residues, and it
may also be possible to have a much larger hydrophobic
group in place of the indolyl ring that twists its way into
the additional space. COX-2 specific inhibitors41,42 take
advantage of small pockets, and selective estrogen recep-
tor modulators like raloxifene43 have very large hydropho-
bic side chains that wind into hydrophobic interiors of the
protein target.
In Table III, the G of hydration for the mimic is estimated
to be 4.0 kcal/mol (Egas  Gsolvation  TS). It is possible that
the disubstituted tetramer may have poor solubility for some
binding assays, but the hydrophobicity may result in good
Fig. 6. A comparison of the similar topologies of the mimic and
nutlin2.13 (A) Central, 5-membered ring. (B) Rings with significant
exocyclic groups to play the role of L26 in p53. (C) Aromatic rings play the
role of W23. (D) Additional rings present hydrophobic groups (E) to
occupy the F19 pocket of MDM2. Regions that are dissimilar are marked
with boxes.
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bioavailability. Functional groups introduced to complement
the sites mentioned below could alter the solubility. How-
ever, such modifications should be carefully chosen, so that
pharmacokinetic properties are also considered.
Further optimization of this mimic could take advantage
of additional interactions available in the binding site.
Inspection of the snapshots from the MD simulation of the
mimic–MDM2 complex reveals potential hydrogen-bond-
ing interactions within the binding cleft that could be used
to further improve binding. The backbone oxygen on Q72
does not participate in a hydrogen bond. The side chain of
Q72 does form a hydrogen bond to p53, but even with the
natural ligand, the backbone oxygen is not complemented.
The backbone oxygen of V93 is also available to interact
with a ligand, but it is more solvent-exposed. A hydrogen
bond between the mimic and the backbone of Q72 or V93
could enhance binding in a manner not seen in p53, and an
additional interaction with the backbone of MDM2 should
be less prone to contributing to binding hotspots.
CONCLUSIONS
We have successfully applied the GBSA method to esti-
mate the binding free energy of a p53 helix to MDM2 as 7.4
kcal/mol. This is in very good agreement with the experi-
ments (6.6–8.8 kcal/mol) and implies that we have reli-
able methodology for modeling this system. We have de-
signed a novel mimic of p53 based on a tetramer of -proline,
a promising peptidomimetic oligomer. Its estimated free
energy of binding is 8.8 kcal/mol, indicating that this mimic
could be a potent inhibitor of MDM2. MD simulations and
computational alanine-scanning studies for both p53–MDM2
and the mimic–MDM2 complexes reveal the common bind-
ing hotspots could be L54, I61, M62, G58, and V93. Y67 is
predicted to be a hotspot for binding both ligands, but it is
more significant for the mimic. This makes it possible for Y67
to be the site for escape mutants that evade our mimic. This
could be taken into consideration when trying to improve the
mimic.
The mimic was compared to nutlin2, a new inhibitor of
p53–MDM2 binding. Interesting similarities were found,
and comparisons between the 2 structures revealed poten-
tial modifications that could be made to improve the mimic
and possibly the nutlins. Second-generation designs could
take advantage of potential hydrogen-bonding interac-
tions in the cleft or exploit an internal hydrophobic pocket
in MDM2. [Plots of the potential energies over the course
of the MD simulations and the parameters for the mimic
are provided in supplementary materials which can be
Fig. 7. Two views are used to show the similarity and differences between the mimic (ball-and-stick
configuration with green carbons) and nutlin2. This is an overlay of the complexes of nutlin2–MDM213 and
mimic–MDM2, but for clarity, the proteins are not shown.
Fig. 8. An additional hydrophobic pocket is available within human
MDM2 (lower lefthand quadrant). The pocket is seen within (A) the
p53–MDM225 and (B) the nutlin2–MDM213 complexes. Its size is variable,
and it may be possible to design new inhibitors to take advantage of the
additional space within the hydrophobic core.
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found at http://www.interscience.wiley.com/jpages/0887-
3585/Suppmat/index.html]
NOTE ADDED IN PROOF
Schepartz and coworkers44 have recently created a
-peptide mimic of p53–MDM2 binding.
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